EP1282440A1 - Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumor agents - Google Patents

Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumor agents

Info

Publication number
EP1282440A1
EP1282440A1 EP01929585A EP01929585A EP1282440A1 EP 1282440 A1 EP1282440 A1 EP 1282440A1 EP 01929585 A EP01929585 A EP 01929585A EP 01929585 A EP01929585 A EP 01929585A EP 1282440 A1 EP1282440 A1 EP 1282440A1
Authority
EP
European Patent Office
Prior art keywords
her2
aromatase inhibitor
antibody against
human
exemestane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01929585A
Other languages
German (de)
French (fr)
Inventor
Giorgio Massimini
Gabriella Piscitelli
Dinesh Purandare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia Italia SpA
Pharmacia and Upjohn SpA
Pharmacia and Upjohn Co
Upjohn Co
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA, Pharmacia and Upjohn SpA, Pharmacia and Upjohn Co, Upjohn Co, Pharmacia and Upjohn Co LLC filed Critical Pharmacia Italia SpA
Publication of EP1282440A1 publication Critical patent/EP1282440A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents are aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
  • the present invention concerns the treatment of hormone dependent disorders characterized by the overexpression of HE 2. More specifically, the invention concerns the treatment of a human being susceptible to or diagnosed
  • a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2 comprising a therapeutically effective amount of an aromatase inhibitor and a therapeutically effective amount of an antibody against HER2 , can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of either a sole aromatase inhibitor or a sole antibody against HER2.
  • a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2 comprising a therapeutically sub- effective amount of an aromatase inhibitor and a therapeutically sub-effective amount of an antibody against HER2
  • the effectiveness of an aromatase inhibitor and an antibody against HER2 is significantly increased without a parallel increased toxicity.
  • the combined therapy of the present invention enhances the therapeutic effects of the aromatase inhibitor and the antibody against HER2 and thus yields more effective and less toxic treatment for hormone- dependent disorders .
  • the present invention provides a new and valuable tool in the therapy of hormone dependent disorders characterized by the overexpression of HER2.
  • hormone dependent disorders characterized by the overexpression of HER2.
  • cancers e.g. breast, cervical, ovarian and endometrial cancers, and endometriosis .
  • endometriosis e.g. breast cancer in a human being, in particular a female.
  • the present invention provides, as a first object, a pharmaceutical composition comprising an aromatase inhibitor and an antibody against HER2 , having a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2.
  • the present invention also provides the use of an aromatase inhibitor in the manufacture of a pharmaceutical composition for treatment of an hormone-dependent disorder characterized by the overexpression of HER2 , the treatment additionally comprising the administration of a composition comprising an antibody against HER2, in amounts effective to produce a superadditive effect.
  • aromatase inhibitors are exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, 1-methyl-1, 4-androstadiene-3 , 17- dione (MAD) , ketokonazole, fadrozole, letrozole, vorozole and anastrozole.
  • aromatase inhibitors according to the invention are exemestane, anastrozole and letrozole, in particular exemestane.
  • the aromatase inhibitors cited herein are well known products, which are cited for instance in Cancer-Treat- Res.: 94, 231-254, 1998 and WO 99/30708.
  • an antibody against HER2 can be either and "intact” antibody or a fragment thereof.
  • antibody is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.
  • Antibody fragments comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single- chain antbody molecules; and multispecific antibodies formed from antibody fragments.
  • a preferred example of an antibody against HER2 is trastuzumab.
  • the recombinant humanized monoclonal antibody anti-HER2 trastuzumab (Herceptin ® ) is described in various scientific publications, for example Cancer Res., 1998, 58: 2825-2831.
  • the present invention also provides a product comprising an aromatase inhibitor and an antibody against HER2 , as combined preparation for simultaneous, separate or sequential administration, in amounts to produce a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2.
  • the present invention provides a kit comprising, in a suitable container means, a pharmaceutical composition containing an aromatase inhibitor, as an active agent, and an antibody against HER2 , as a further active agent, in amounts to produce a synergistic or superadditive therapeutic activity against hormone-dependent disorder characterized by the overexpression of HER2.
  • a further aspect of the present invention is to provide a method of treating a human being, particularly a female, suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor and an antibody against HER2 , in amounts effective to produce a superadditive or synergistic therapeutic effect.
  • a still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an aromatase inhibitor in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing HER2 , the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an antibody against HER2 , in amounts effective to produce a superadditive or synergistic antitumor effect.
  • a still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an antibody against HER2 in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing HER2 , the method comprising administering to said human being a combined preparation comprising an antibody against HER2 and an aromatase inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect.
  • a superadditive or synergistic antitumor effect is meant the inhibition of the growth tumor, preferably the complete regression of the tumor, by administering a combination of an aromatase inhibitor, as defined above, and an antibody against a HER2, to a human being, particularly a human female.
  • composition having therefore a potentiated antitumor (superadditive) activity with respect to products containing either an aromatase inhibitor or an antibody against HER2.
  • administered or “administering” as used herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration.
  • parenteral is meant intravenous, subcutaneous, intradermal or intramuscular administration.
  • Oral administration includes administering the costituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
  • Parenteral administration includes administering the constituents of the combined preparation by subcutaneous, subcutaneous, intravenous or intramuscular injections.
  • the actual preferred method and order of administration of the combined preparations of the invention may vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the antibody against the growth factor receptor being utilized, the particular cancer being treated and the particular patient being treated.
  • the dosage ranges for the administration of the combined preparation may vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
  • the dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to changes in conditions and/or in light of other clinical conditions .
  • the aromatase inhibitor may be administered simultaneously with the antibody against HER2 or the compounds may be administered sequentially, in either order.
  • An effective amount of an aromatase inhibitor antitumor agent may vary from about 0.5 to about 500 mg pro dose 1-2 times a day.
  • Exemestane for example, may be administered orally in a dosage range varying from about 5 to about 200 mg, and particularly, from about 10 to about 25 mg, or parenterally from about 50 to about 500 mg, in particular from about 100 to about 250 mg.
  • Fadrozole for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
  • Letrozole may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg.
  • Formestane for example, may be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg.
  • Anastrozole for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
  • the course of therapy generally employed is from about 1 to about 1000 mg/m 2 of body surface area. More preferably, the course therapy employed is from about 50 to about 500 mg/m 2 of body surface area .
  • the therapy method according to the present invention is, in particular, suitable for treating a human being suffering from hormone dependent disorders, characterized by the overexpression of HER2.
  • Typical examples of such disorders are endometriosis and tumors, like ovarian, cervical and endometrial cancers in a human female or breast cancer in a human being, in particular a female.
  • an aromatase inhibitor, according to the invention preferably exemestane
  • a recombinant humanized anti-HER2 antibody for example the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, can be suitable for the treatment of patients with cancers over-expressing the
  • HER2 protein for example, for patient with breast cancer, in particular with metastatic breast cancer, over- expressing the HER2 protein.
  • a pharmaceutically composition containing an aromatase inhibitor and/or an antibody against HER2 can be prepared according to well known techniques to those skilled in the art.
  • a pharmaceutical composition containing exemestane can be prepared according to US 4,808,616.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating a human being suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor e.g. exemestane, fadrozole, letrozole and anastrozole and an antibody against HER2 e.g. trastuzumab, in amounts effective to produce a superadditive or synergistic therapeutic effect.

Description

aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
The present invention concerns the treatment of hormone dependent disorders characterized by the overexpression of HE 2. More specifically, the invention concerns the treatment of a human being susceptible to or diagnosed
10 with a disorder characterized by the overexpression of HER2 with a combination of an anti-HER2 antibody and an aromatase inhibitor.
Proto-oncogens that encode growth factors and growth factors receptors have been identified to play important
15 roles in the pathogenesis of various malignancies, including breast cancer. In particular numerous studies have demonstrated the prognostic relevance of pl85 (HER2) , which is overexpressed in 10% to 40% of human breast tumors. Moreover a recombinant humanized anti-HER2
20 monoclonal antibody (a humanized version of the murine anti-HER-2 antibody 4D5 , referred to as Herceptin®) has been found clinically active in patients with HER2- overexpressing breast cancer (J. Clin. Oncol. 14:737-744, 1996) . Also the utility of aromatase inhibitors is well
25 acknowledged in anticancer therapy. However, it is also well known in the art that administration to a patient of therapeutically effective amounts of aromatase inhibitors can cause considerable side effects. The major toxicities are for instance lethargy, hot flashes, rash, transient
30 leukopenia, dizzines, nausea, constipation and vomiting. On the other hand, also administration to a patient of therapeutically effective amounts of an antibody against HER2 can similarly cause considerable side effects, e.g. hypersensitivity, alterations of renal function,
35 myocardial lesions and cardiotoxicity in general. The inventors of the present invention have found that a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2 , comprising a therapeutically effective amount of an aromatase inhibitor and a therapeutically effective amount of an antibody against HER2 , can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of either a sole aromatase inhibitor or a sole antibody against HER2. Similarly they have found that a combination therapy of an hormone dependent disorder characterized by the overexpression of HER2 , comprising a therapeutically sub- effective amount of an aromatase inhibitor and a therapeutically sub-effective amount of an antibody against HER2 , can produce substantially the same therapeutic effect, which is obtainable by single administration of a therapeutically effective amount of either an aromatase inhibitor or an antibody against HER2. The most important, they have found that such newly obtained therapeutic effect is not paralleled by the toxic effects, otherwise caused by single administrations of either therapeutically effective amounts of an aromatase inhibitor or therapeutically effective amounts of an anti- HER2 antibody. In view of the above, the effectiveness of an aromatase inhibitor and an antibody against HER2 is significantly increased without a parallel increased toxicity. In other words, the combined therapy of the present invention enhances the therapeutic effects of the aromatase inhibitor and the antibody against HER2 and thus yields more effective and less toxic treatment for hormone- dependent disorders .
Accordingly, the present invention provides a new and valuable tool in the therapy of hormone dependent disorders characterized by the overexpression of HER2. The advantages provided by the present invention can be appreciated by their preferred features, described herebelow. Examples of such disorders are cancers, e.g. breast, cervical, ovarian and endometrial cancers, and endometriosis . However such disorder is preferably breast cancer in a human being, in particular a female.
Accordingly, the present invention provides, as a first object, a pharmaceutical composition comprising an aromatase inhibitor and an antibody against HER2 , having a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2.
The present invention also provides the use of an aromatase inhibitor in the manufacture of a pharmaceutical composition for treatment of an hormone-dependent disorder characterized by the overexpression of HER2 , the treatment additionally comprising the administration of a composition comprising an antibody against HER2, in amounts effective to produce a superadditive effect.
Examples of aromatase inhibitors according to the invention are exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, 1-methyl-1, 4-androstadiene-3 , 17- dione (MAD) , ketokonazole, fadrozole, letrozole, vorozole and anastrozole.
Preferred examples of aromatase inhibitors according to the invention are exemestane, anastrozole and letrozole, in particular exemestane. The aromatase inhibitors cited herein are well known products, which are cited for instance in Cancer-Treat- Res.: 94, 231-254, 1998 and WO 99/30708.
Unless otherwise indicated, the terms "HER2" and ErbB2" when used herein refer to the human protein and are used interchangeably.
An antibody against HER2, according to the invention, can be either and "intact" antibody or a fragment thereof. The term "antibody" is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity. "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single- chain antbody molecules; and multispecific antibodies formed from antibody fragments.
A preferred example of an antibody against HER2 is trastuzumab.
The recombinant humanized monoclonal antibody anti-HER2 trastuzumab (Herceptin®) is described in various scientific publications, for example Cancer Res., 1998, 58: 2825-2831.
The present invention also provides a product comprising an aromatase inhibitor and an antibody against HER2 , as combined preparation for simultaneous, separate or sequential administration, in amounts to produce a synergistic or superadditive therapeutic activity against an hormone-dependent disorder characterized by the overexpression of HER2. In a further aspect, the present invention provides a kit comprising, in a suitable container means, a pharmaceutical composition containing an aromatase inhibitor, as an active agent, and an antibody against HER2 , as a further active agent, in amounts to produce a synergistic or superadditive therapeutic activity against hormone-dependent disorder characterized by the overexpression of HER2.
A further aspect of the present invention is to provide a method of treating a human being, particularly a female, suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor and an antibody against HER2 , in amounts effective to produce a superadditive or synergistic therapeutic effect.
A still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an aromatase inhibitor in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing HER2 , the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an antibody against HER2 , in amounts effective to produce a superadditive or synergistic antitumor effect.
A still further aspect of the present invention is to provide a method for lowering the side effects (adverse reactions) caused by antitumor therapy with an antibody against HER2 in a human being, particularly a female, suffering from an hormone-dependent tumor overexpressing HER2 , the method comprising administering to said human being a combined preparation comprising an antibody against HER2 and an aromatase inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect.
By the term "a superadditive or synergistic antitumor effect" as used herein is meant the inhibition of the growth tumor, preferably the complete regression of the tumor, by administering a combination of an aromatase inhibitor, as defined above, and an antibody against a HER2, to a human being, particularly a human female.
Said preparation having therefore a potentiated antitumor (superadditive) activity with respect to products containing either an aromatase inhibitor or an antibody against HER2. By the term "administered" or "administering" as used herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration. By "parenteral" is meant intravenous, subcutaneous, intradermal or intramuscular administration.
Oral administration includes administering the costituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like. Parenteral administration includes administering the constituents of the combined preparation by subcutaneous, subcutaneous, intravenous or intramuscular injections.
The actual preferred method and order of administration of the combined preparations of the invention may vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the antibody against the growth factor receptor being utilized, the particular cancer being treated and the particular patient being treated.
The dosage ranges for the administration of the combined preparation may vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to changes in conditions and/or in light of other clinical conditions .
In the combined method of treatment according to the subject invention, the aromatase inhibitor may be administered simultaneously with the antibody against HER2 or the compounds may be administered sequentially, in either order.
An effective amount of an aromatase inhibitor antitumor agent may vary from about 0.5 to about 500 mg pro dose 1-2 times a day. Exemestane, for example, may be administered orally in a dosage range varying from about 5 to about 200 mg, and particularly, from about 10 to about 25 mg, or parenterally from about 50 to about 500 mg, in particular from about 100 to about 250 mg. Fadrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
Letrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg. Formestane, for example, may be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg. Anastrozole, for example, may be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg. In the method of the subject invention, for example for the administration of the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, the course of therapy generally employed is from about 1 to about 1000 mg/m2 of body surface area. More preferably, the course therapy employed is from about 50 to about 500 mg/m2 of body surface area .
The therapy method according to the present invention is, in particular, suitable for treating a human being suffering from hormone dependent disorders, characterized by the overexpression of HER2. Typical examples of such disorders are endometriosis and tumors, like ovarian, cervical and endometrial cancers in a human female or breast cancer in a human being, in particular a female. More in particular, the combined use of an aromatase inhibitor, according to the invention, preferably exemestane, and a recombinant humanized anti-HER2 antibody, for example the recombinant humanized monoclonal antibody anti-HER2 trastuzumab, can be suitable for the treatment of patients with cancers over-expressing the
HER2 protein, for example, for patient with breast cancer, in particular with metastatic breast cancer, over- expressing the HER2 protein.
Suitable modifications and adaptations of a variety of conditions and parameters normally encountered in clinical therapy which are obvious to those skilled in the art are within the scope of this invention.
A pharmaceutically composition containing an aromatase inhibitor and/or an antibody against HER2 can be prepared according to well known techniques to those skilled in the art. For instance a pharmaceutical composition containing exemestane can be prepared according to US 4,808,616.

Claims

Use of an aromatase inhibitor in the manufacture of a pharmaceutical composition for treatment of an hormone-dependent disorder characterized by the overexpression of HER2 , the treatment additionally comprising the administration of a composition comprising an antibody against HER2 , in amounts effective to produce a superadditive effect.
Use, according to claim 1, wherein the disorder is breast, cervical, ovarian and endometrial cancers, and endometriosis .
3. Use, according to claim 2, wherein the disorder is breast cancer.
4. Use, according to claim 1, wherein the aromatase inhibitor is selected from exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, 1-methyl-l, 4-androstadiene-3 , 17-dione (MAD) , ketokonazole, fadrozole, letrozole, vorozole and anastrozole .
5. Use, according to claim 1, wherein the aromatase inhibitor is exemestane.
6. Use, according to claim 1, wherein the antibody against HER2 is trastuzumab.
7. Use, according to claim 3, wherein the aromatase inhibitor is exemestane and the antibody against HER2 is trastuzumab.
8. A method of treating a human being suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor and an antibody against HER2 , in amounts effective to produce a superadditive or synergistic therapeutic effect.
9. A method for lowering the side effects caused by antitumor therapy with an aromatase inhibitor in a human being suffering from an hormone-dependent tumor overexpressing HER2 , the method comprising administering to said human being a combined preparation comprising an aromatase inhibitor and an antibody against HER2 , in amounts effective to produce a superadditive or synergistic antitumor effect.
10. A method for lowering the side effects caused by antitumor therapy with an antibody against HER2 in a human being suffering from an hormone-dependent tumor overexpressing HER2 , the method comprising administering to said human being a combined preparation comprising an antibody against HER2 and an aromatase inhibitor, in amounts effective to produce a superadditive or synergistic antitumor effect.
11. A method according to claim 8, wherein the disorder is breast, cervical, ovarian and endometrial cancers, and endometriosis .
12. A method according to claim 8, wherein the disorder is breast cancer.
13. A method according to claim 8, wherein the aromatase inhibitor is selected from exemestane, aminoglutethimide, roglethimide, pyridoglutethimide, anastrazole, trilostane, testolactone, formestane, atamestane, 1-methyl-l, 4-androstadiene-3 , 17-dione (MAD) , ketokonazole, fadrozole, letrozole, vorozole and anastrozole.
14. A method according to claim 8, wherein the aromatase inhibitor is exemestane.
15. A method according to claim 8, wherein the antibody against HER2 is trastuzumab.
16. A method according to claim 8, wherein the aromatase inhibitor is exemestane and the antibody against HER2 is trastuzumab.
EP01929585A 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumor agents Withdrawn EP1282440A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
US571355 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (en) 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents

Publications (1)

Publication Number Publication Date
EP1282440A1 true EP1282440A1 (en) 2003-02-12

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01929585A Withdrawn EP1282440A1 (en) 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumor agents

Country Status (20)

Country Link
EP (1) EP1282440A1 (en)
JP (1) JP2003533490A (en)
KR (1) KR20030014223A (en)
CN (1) CN1429118A (en)
AU (1) AU784617B2 (en)
BR (1) BR0110732A (en)
CA (1) CA2409652A1 (en)
CZ (1) CZ20023748A3 (en)
EA (1) EA005931B1 (en)
EE (1) EE200200622A (en)
HK (1) HK1054200A1 (en)
HU (1) HUP0301877A2 (en)
IL (1) IL152389A0 (en)
MX (1) MXPA02011194A (en)
NO (1) NO20025302L (en)
NZ (1) NZ523004A (en)
PL (1) PL360153A1 (en)
SK (1) SK16022002A3 (en)
WO (1) WO2001087334A1 (en)
ZA (1) ZA200209815B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
MXPA03006607A (en) * 2001-01-26 2003-09-22 Upjohn Co Combined method for treating hormono-dependent disorders.
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
AU2003218600C1 (en) 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
RU2005101622A (en) * 2002-07-01 2006-01-27 Савиент Фармасьютикалс, Инк (Us) COMPOSITIONS AND METHODS OF THERAPEUTIC TREATMENT
FR2844455B1 (en) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES
KR20080019733A (en) * 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 Combination therapy for non-hematologic malignancies using anti-IGF-1AL antibody
CN102580084B (en) 2005-01-21 2016-11-23 健泰科生物技术公司 The fixed dosage of HER antibody is administered
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
SI2132573T1 (en) 2007-03-02 2014-07-31 Genentech, Inc. Predicting response to a her dimerisation inhbitor based on low her3 expression
PL2171090T3 (en) 2007-06-08 2013-09-30 Genentech Inc Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102421448A (en) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102068429B (en) * 2010-12-28 2011-12-14 西南大学 Application of fadrozole in inducing transformation of differentiated ovary of tilapia mossambica into functional testis and induction method thereof
MX2014001766A (en) 2011-08-17 2014-05-01 Genentech Inc Neuregulin antibodies and uses thereof.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (en) 2011-11-30 2020-10-20 Genentech, Inc. erbb3 mutations in cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
KR102291355B1 (en) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Identification of patients in need of pd-l1 inhibitor cotherapy
CA2965372C (en) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
JP2018534291A (en) 2015-10-22 2018-11-22 ハバフ セラピューティクス ピーティーワイ エルティーディー Method for reducing mammography breast density and / or risk of breast cancer
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN107417791B (en) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 Anti-human ErbB2 bispecific antibody, preparation method and application thereof
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0187334A1 *

Also Published As

Publication number Publication date
ZA200209815B (en) 2003-12-03
AU5630901A (en) 2001-11-26
CA2409652A1 (en) 2001-11-22
MXPA02011194A (en) 2003-03-10
HUP0301877A2 (en) 2003-09-29
NO20025302D0 (en) 2002-11-05
PL360153A1 (en) 2004-09-06
JP2003533490A (en) 2003-11-11
KR20030014223A (en) 2003-02-15
AU784617B2 (en) 2006-05-18
NZ523004A (en) 2004-09-24
EE200200622A (en) 2004-06-15
HK1054200A1 (en) 2003-11-21
CN1429118A (en) 2003-07-09
EA200201213A1 (en) 2003-04-24
NO20025302L (en) 2002-11-05
IL152389A0 (en) 2003-05-29
SK16022002A3 (en) 2003-04-01
CZ20023748A3 (en) 2003-04-16
BR0110732A (en) 2003-02-04
EA005931B1 (en) 2005-08-25
WO2001087334A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
AU784617B2 (en) Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents
US20050032759A1 (en) Antitumor combined therapy
AU2012229147B2 (en) Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
JP2023085422A (en) Combining ErbB-2/ErbB-3 bispecific antibodies with endocrine therapy for breast cancer
WO2017205216A1 (en) Combination of pembrolizumab and abemaciclib for the treatment of cancer
MXPA06008942A (en) Anti-epcam immunoglobulins.
Perry et al. Trastuzumab
CN120344271A (en) Anti-HER2 antibody-drug conjugates for breast cancer
CN121513160A (en) Application of Fusobacterium-specific antimicrobial peptides in the preparation of drugs that enhance the efficacy of antitumor immunotherapy
Nozawa et al. Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
HK40027114B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
HK40027114A (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
NZ614427B2 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021210

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY LLC

Owner name: PHARMACIA ITALIA S.P.A.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY LLC

Owner name: PFIZER ITALIA S.R.L.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY LLC

Owner name: PFIZER ITALIA S.R.L.

17Q First examination report despatched

Effective date: 20080818

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090310